Literature DB >> 31899796

Refined National Institutes of Health response algorithm for chronic graft-versus-host disease in joints and fascia.

Yoshihiro Inamoto1,2, Stephanie J Lee2, Lynn E Onstad2, Mary E D Flowers2, Betty K Hamilton3, Madan H Jagasia4, Paul J Martin2, Steven Z Pavletic5, Joseph A Pidala6, Iskra Pusic7, Georgia B Vogelsang8, Daniel Wolff9, Paul A Carpenter2.   

Abstract

Implementation of the 2014 National Institutes of Health (NIH) response algorithm for joint/fascia graft-versus-host disease (GVHD) has identified real-world limits to its application. To refine the 2014 NIH response algorithm, we analyzed multicenter prospective observational data from the Chronic GVHD Consortium. The training cohort included 209 patients and the replication cohort included 191 patients with joint/fascia involvement during their course of chronic GVHD. Linear mixed models with random patient effect were used to evaluate correlations between response categories and clinician- or patient-perceived changes in joint status as an anchor of response. Analysis of the training cohort showed that a 2-point change in total photographic range of motion (P-ROM) score was clinically meaningful. The results also suggested that a change from 0 to 1 on the NIH joint/fascia score should not be considered as worsening and suggested that both the NIH joint/fascia score and total P-ROM score, but not individual P-ROM scores, should be used for response assessment. On the basis of these results, we developed an evidence-based refined algorithm, the utility of which was examined in an independent replication cohort. Using the refined algorithm, ∼40% of responses were reclassified, largely mitigating most divergent responses among individual joints and changes from 0 to 1 on the NIH joint/fascia score. The refined algorithm showed robust point estimates and tighter 95% confidence intervals associated with clinician- or patient-perceived changes, compared with the 2014 NIH algorithm. The refined algorithm provides a superior, evidence-based method for measuring therapeutic response in joint/fascia chronic GVHD.

Entities:  

Mesh:

Year:  2020        PMID: 31899796      PMCID: PMC6960471          DOI: 10.1182/bloodadvances.2019000918

Source DB:  PubMed          Journal:  Blood Adv        ISSN: 2473-9529


  17 in total

1.  Fixed effects, random effects and GEE: what are the differences?

Authors:  Joseph C Gardiner; Zhehui Luo; Lee Anne Roman
Journal:  Stat Med       Date:  2009-01-30       Impact factor: 2.373

2.  National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report.

Authors:  Alexandra H Filipovich; Daniel Weisdorf; Steven Pavletic; Gerard Socie; John R Wingard; Stephanie J Lee; Paul Martin; Jason Chien; Donna Przepiorka; Daniel Couriel; Edward W Cowen; Patricia Dinndorf; Ann Farrell; Robert Hartzman; Jean Henslee-Downey; David Jacobsohn; George McDonald; Barbara Mittleman; J Douglas Rizzo; Michael Robinson; Mark Schubert; Kirk Schultz; Howard Shulman; Maria Turner; Georgia Vogelsang; Mary E D Flowers
Journal:  Biol Blood Marrow Transplant       Date:  2005-12       Impact factor: 5.742

3.  Incidence, risk factors, and outcomes of sclerosis in patients with chronic graft-versus-host disease.

Authors:  Yoshihiro Inamoto; Barry E Storer; Effie W Petersdorf; J Lee Nelson; Stephanie J Lee; Paul A Carpenter; Brenda M Sandmaier; John A Hansen; Paul J Martin; Mary E D Flowers
Journal:  Blood       Date:  2013-04-01       Impact factor: 22.113

4.  Ibrutinib for chronic graft-versus-host disease after failure of prior therapy.

Authors:  David Miklos; Corey S Cutler; Mukta Arora; Edmund K Waller; Madan Jagasia; Iskra Pusic; Mary E Flowers; Aaron C Logan; Ryotaro Nakamura; Bruce R Blazar; Yunfeng Li; Stephen Chang; Indu Lal; Jason Dubovsky; Danelle F James; Lori Styles; Samantha Jaglowski
Journal:  Blood       Date:  2017-09-18       Impact factor: 22.113

5.  Sclerotic-type chronic GVHD of the skin: clinical risk factors, laboratory markers, and burden of disease.

Authors:  Kathryn J Martires; Kristin Baird; Seth M Steinberg; Lana Grkovic; Galen O Joe; Kirsten M Williams; Sandra A Mitchell; Manuel Datiles; Fran T Hakim; Steven Z Pavletic; Edward W Cowen
Journal:  Blood       Date:  2011-07-26       Impact factor: 22.113

6.  Measuring therapeutic response in chronic graft-versus-host disease. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. The 2014 Response Criteria Working Group report.

Authors:  Stephanie J Lee; Daniel Wolff; Carrie Kitko; John Koreth; Yoshihiro Inamoto; Madan Jagasia; Joseph Pidala; Attilio Olivieri; Paul J Martin; Donna Przepiorka; Iskra Pusic; Fiona Dignan; Sandra A Mitchell; Anita Lawitschka; David Jacobsohn; Anne M Hall; Mary E D Flowers; Kirk R Schultz; Georgia Vogelsang; Steven Pavletic
Journal:  Biol Blood Marrow Transplant       Date:  2015-03-19       Impact factor: 5.742

7.  Fasciitis in chronic graft-versus-host disease. A clinicopathologic study of 14 cases.

Authors:  A Janin; G Socie; A Devergie; S Aractingi; H Esperou; O Vérola; E Gluckman
Journal:  Ann Intern Med       Date:  1994-06-15       Impact factor: 25.391

Review 8.  Chronic graft-versus-host disease.

Authors:  Stephanie J Lee; Georgia Vogelsang; Mary E D Flowers
Journal:  Biol Blood Marrow Transplant       Date:  2003-04       Impact factor: 5.742

9.  Design and Patient Characteristics of the Chronic Graft-versus-Host Disease Response Measures Validation Study.

Authors: 
Journal:  Biol Blood Marrow Transplant       Date:  2018-02-21       Impact factor: 5.742

10.  A phase II/III randomized, multicenter trial of prednisone/sirolimus versus prednisone/ sirolimus/calcineurin inhibitor for the treatment of chronic graft-versus-host disease: BMT CTN 0801.

Authors:  Paul A Carpenter; Brent R Logan; Stephanie J Lee; Daniel J Weisdorf; Laura Johnston; Luciano J Costa; Carrie L Kitko; Javier Bolaños-Meade; Stefanie Sarantopoulos; Amin M Alousi; Sunil Abhyankar; Edmund K Waller; Adam Mendizabal; Jiaxi Zhu; Kelly A O'Brien; Aleksandr Lazaryan; Juan Wu; Eneida R Nemecek; Steven Z Pavletic; Corey S Cutler; Mary M Horowitz; Mukta Arora
Journal:  Haematologica       Date:  2018-06-28       Impact factor: 9.941

View more
  2 in total

Review 1.  Graft versus host disease-related eosinophilic fasciitis: cohort description and literature review.

Authors:  Cristina Hidalgo Calleja; Daniel Martín Hidalgo; Concepción Román Curto; Lourdes Vázquez López; Estefanía Pérez López; Mónica Cabrero Calvo; Ana África Martín López; María Dolores Caballero Barrigón; Lucía Lopez-Corral
Journal:  Adv Rheumatol       Date:  2022-08-23

2.  National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IIa. The 2020 Clinical Implementation and Early Diagnosis Working Group Report.

Authors:  Carrie L Kitko; Joseph Pidala; Hélène M Schoemans; Anita Lawitschka; Mary E Flowers; Edward W Cowen; Eric Tkaczyk; Nosha Farhadfar; Sandeep Jain; Philipp Steven; Zhonghui K Luo; Yoko Ogawa; Michael Stern; Greg A Yanik; Geoffrey D E Cuvelier; Guang-Shing Cheng; Shernan G Holtan; Kirk R Schultz; Paul J Martin; Stephanie J Lee; Steven Z Pavletic; Daniel Wolff; Sophie Paczesny; Bruce R Blazar; Stephanie Sarantopoulos; Gerard Socie; Hildegard Greinix; Corey Cutler
Journal:  Transplant Cell Ther       Date:  2021-04-09
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.